Woodline Partners LP Grows Stock Position in Encompass Health Co. (NYSE:EHC)

Woodline Partners LP boosted its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 184,473 shares of the company's stock after buying an additional 56,817 shares during the period. Woodline Partners LP owned approximately 0.18% of Encompass Health worth $17,036,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Park Avenue Securities LLC grew its position in Encompass Health by 44.7% in the 4th quarter. Park Avenue Securities LLC now owns 6,737 shares of the company's stock valued at $622,000 after acquiring an additional 2,082 shares during the last quarter. Merit Financial Group LLC bought a new position in Encompass Health in the 4th quarter valued at $374,000. Ameritas Advisory Services LLC bought a new position in Encompass Health in the 4th quarter valued at $380,000. MassMutual Private Wealth & Trust FSB grew its position in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after acquiring an additional 137 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its position in Encompass Health by 0.3% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 302,272 shares of the company's stock valued at $27,915,000 after acquiring an additional 830 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Trading Down 1.6%

Shares of NYSE EHC opened at $119.77 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The stock has a market capitalization of $12.07 billion, a P/E ratio of 26.85, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a 1-year low of $82.74 and a 1-year high of $121.96. The business has a fifty day moving average price of $107.01 and a 200 day moving average price of $101.17.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.12 EPS. Equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is currently 14.05%.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the sale, the chief executive officer now directly owns 527,070 shares in the company, valued at approximately $64,054,817.10. This trade represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the sale, the insider now owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 132,663 shares of company stock worth $16,034,082 in the last three months. 2.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EHC has been the topic of several research analyst reports. Barclays upped their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Truist Financial reissued a "buy" rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. StockNews.com raised Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, May 11th. Royal Bank of Canada increased their price target on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Finally, KeyCorp increased their price target on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Encompass Health has an average rating of "Buy" and a consensus target price of $120.86.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.